Saliva Sampling and Testing Strategies for Screening AD Biomarkers Using a Portable Antibody Functionalized Bioanalyzer Platform

Abstract

Background: Saliva collection has been explored for non‐invasive AD biomarker testing in several studies (Kirmess et al.,2021, De Meyer et al.,2020), however, challenges persist in maintaining consistent sampling and reliable benchmarking for the low salivary Aß42 concentration in healthy controls (0.6‐66.1pg/ml; Agnello et al.